Tenax Therapeutics (TENX) 10% Owner LLC Buys $507K of Stock

ADAR1 Capital Management, LLC bought 336,528 shares of Tenax Therapeutics, Inc. (TENX) on October 19, 2026. According to a Form 4 filing with the SEC, the shares were acquired at an average price of $1.51, bringing the total transaction value to roughly $507,013.

TENX Tenax Therapeutics, Inc.

$1.63 ▼ -85.25% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside ADAR1 Capital Management's Tenax Therapeutics Trade

The purchase expanded the institutional owner's position by a 5.16% increase. Following the trade, ADAR1 Capital Management, LLC holds 6,860,679 shares of the company. The transaction was filed two business days after the trade took place.

Other Institutional Activity in Tenax Therapeutics

Other large funds have also adjusted their positions in the company during recent reporting periods. Vivo Capital, LLC grew its holdings by 2,291,667 shares, ending with 2,500,000 shares worth about $4,074,999. Perceptive Advisors Llc added 252,206 shares for a total of 1,700,000 shares valued at roughly $2,770,999. Millennium Management Llc raised its stake by 342,334 shares, finishing with 876,230 shares worth about $1,428,254. Meanwhile, Ikarian Capital, LLC reduced its position by 229,971 shares to hold 787,600 shares valued at about $1,283,787. Candriam S.C.A. grew its holdings by 374,794 shares, ending with 749,588 shares worth about $1,221,828.

Tenax Therapeutics, Inc. Stock Down 13.7%

The stock recently traded around $1.64 as of October 21, 2026, which puts it up about 20.6% since closing at $1.36 on October 16, 2026.

Recent Earnings

The company reported a trailing-twelve-month loss with an EPS of -$1.48.

Insider Buying and Selling at Tenax Therapeutics, Inc.

Several insiders made purchases prior to this event. Adar1 Capital Management LLC bought 900,000 shares on September 3, 2026, for about $1,604,160. Chief Financial Officer Thomas R Staab II acquired 5,675 shares on September 11, 2026, valued at roughly $10,981. Chief Executive Officer Christopher Thomas Giordano picked up 10,850 shares on September 15, 2026, worth about $20,087. Director Declan Doogan added 53,000 shares on September 16, 2026, for approximately $101,760.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock earlier in the second half of the year. Chardan Capital downgraded the stock to a Neutral rating with a $5.0 target on August 11, 2026. Canaccord Genuity kept a Buy rating and set a $4.0 target on August 11, 2026. Guggenheim maintained a Buy rating with a $4.0 target on August 11, 2026, before later moving to a Neutral rating on August 31, 2026. Evercore ISI Group moved to an In-Line rating with a $5.0 target on August 11, 2026.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a drug development company focused on creating treatments for cardiopulmonary diseases. The firm works on therapies addressing pulmonary hypertension and heart failure conditions.

Bottom Line

Investors will continue to monitor SEC filings to track how large owners adjust their positions in the stock. No financial advice is implied by these transactions.